mbiomics Raises €30M Series A to Advance Microbiome Cancer Therapy
Munich techbio company mbiomics completes €30M Series A funding round
The Munich-based techbio company mbiomics garnered €30 million in Series A funding, marking the final closing of a round initiated in March 2023. The investment, led by existing backers MIG Fonds and Bayern Kapital, will be allocated to bolster pharmacological data and accelerate manufacturing development for their lead candidate, MBX-116.
Targeting Advanced Melanoma with Microbiome-Based Therapy
MBX-116 is designed as a live bacterial product intended to enhance the efficacy of immune checkpoint inhibitors in treating advanced melanoma. The company aims to initiate a Phase 1B clinical trial in 2027.
"While the clinical potential of the gut microbiome is well recognized, translating microbiome-based therapeutics into a scalable product has presented a significant engineering challenge." – Dr. Johannes B. Woehrstein, CEO and co-founder of mbiomics
Innovating Microbiome Therapeutics
mbiomics differentiates itself from earlier microbiome interventions, such as faecal microbiota transplants (FMTs), by offering Live Biotherapeutic Products (LBPs). These are oral therapeutics consisting of precisely defined combinations of live bacterial strains, delivered in a pharmaceutical-grade format.
The company’s platform combines artificial intelligence (AI) and machine learning for consortia design, high-resolution analytics, and large-scale co-cultivation and screening capabilities. This rational consortia design approach sets mbiomics apart from previous methods focusing on single-strain probiotics or empirical transplants.
Building the Future of Microbiome Medicine
mbiomics’ MBX-116 is grounded in growing clinical evidence linking the gut microbiome to various conditions, including cancer. By harnessing the power of the microbiome, mbiomics aims to revolutionize cancer treatment and foster a new era of precision medicine.